Revenues in first half 2023 was
"First half 2023 marks a milestone with the acquisition of Thor Medical AS and the strategic repositioning of the Company that comes with the acquisition. I believe the complementary expertise of the combined Company makes us well positioned for becoming a leading global supplier of alpha emitters for the growing market of radiopharmaceuticals, based on our environmentally friendly proprietary technology, creating value for our shareholders and stakeholders over time," says CEO
Going forward, the main business focus for Thor Medical will be to refine the production technology at pilot facilities at Herøya, continue dialog with potential customers in the radiopharma industry for future supply of alpha emitters, as well as to mature the concept for an industrial scale manufacturing facility. The Company will in addition evaluate potential spin-off options for CD37-pipeline.
A presentation of the results, followed by a Q&A session will be held at Carnegie's offices at Aker Brygge, Fjordalleen 16, today at
For further information, please contact:
Brede Ellingsæter, CFO, tel: +47 472 38 440, brede.ellingseter@thormedical.no
About Thor Medical
Thor Medical is an emerging supplier of alpha particle emitters for medical use in cancer therapy. Thor Medical has developed a proprietary technology for the manufacturing of alpha particle emitters from natural resources. Its novel production process requires no irradiation in nuclear reactors, and provides reliable, environmentally friendly supply of radionuclides for the radiopharmaceutical industry. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells. Thor Medical is headquartered in
https://news.cision.com/thor-medical-asa/r/thor-medical-asa-first-half-2023-results,c3826841
https://mb.cision.com/Main/9819/3826841/2264717.pdf
https://mb.cision.com/Public/9819/3826841/89a7c7883b304fff.pdf
(c) 2023 Cision. All rights reserved., source